Wu Kejin, Weng Ziyi, Tao Qinghua, Lin Gufa, Wu Xiangru, Qian Huiqin, Zhang Yichu, Ding Xiaoyan, Jiang Yangfu, Shi Yuenian Eric
Department of Surgery, XinHua Hospital affiliated with Shanghai Second Medical University, Shanghai, China.
Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):920-5.
Gamma-synuclein (SNCG), also referred as breast cancer-specific gene 1, is the third member of a neuronal protein family synuclein. SNCG is highly expressed in human-infiltrating breast carcinomas but not expressed in normal or benign breast tissues. To evaluate the clinical relevance of SNCG expression in breast cancer progression and its correlation with clinical parameters, we analyzed SNCG expression in 79 clinical breast specimens from primary breast cancer, hyperplasia, and fibroadenoma patients by reverse transcription-PCR. The status of estrogen receptor, progesterone receptor, proliferating cell nuclear antigen, and C-erBb2 was also analyzed by immunohistochemistry. Overall SNCG mRNA expression was detectable in 38.8% of breast cancers. However, 79% of stage III/IV breast cancers were positive for SNCG expression, whereas only 15% of stage I/II breast cancers were positive for SNCG expression. In contrast, the expression of SNCG was undetectable in all benign breast lesions. The expression of SNCG was strongly correlated to the stage of breast cancer (P=0.000). This study suggests that the expression of SNCG is stage specific for breast cancer. SNCG is expected to be a useful marker for breast cancer progression and a potential target for breast cancer treatment.
γ-突触核蛋白（SNCG），也被称为乳腺癌特异性基因1，是突触核蛋白神经元蛋白家族的第三个成员。SNCG在人类浸润性乳腺癌中高表达，但在正常或良性乳腺组织中不表达。为了评估SNCG表达在乳腺癌进展中的临床相关性及其与临床参数的相关性，我们通过逆转录聚合酶链反应分析了79例来自原发性乳腺癌、乳腺增生和纤维腺瘤患者的临床乳腺标本中SNCG的表达。还通过免疫组织化学分析了雌激素受体、孕激素受体、增殖细胞核抗原和C-erBb2的状态。总体而言，38.8%的乳腺癌中可检测到SNCG mRNA表达。然而，79%的III/IV期乳腺癌SNCG表达呈阳性，而只有15%的I/II期乳腺癌SNCG表达呈阳性。相比之下，在所有良性乳腺病变中均未检测到SNCG的表达。SNCG的表达与乳腺癌分期密切相关（P = 0.000）。本研究表明，SNCG的表达在乳腺癌中具有分期特异性。SNCG有望成为乳腺癌进展的有用标志物和乳腺癌治疗的潜在靶点。
